Adma Biologics (ADMA) Net Margin (2011 - 2026)
Adma Biologics' (ADMA) quarterly Net Margin came in at 95.77% in Q4 2025, down 13819.0% YoY from N/an in Q4 2024, and down 452.88% on a QoQ basis from 27.14% in Q3 2025.
Adma Biologics (ADMA) Net Margin (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Net Margin data on file, last reported at 95.77% in Q4 2025.
- Quarterly Net Margin fell 13819.0% year-over-year to 95.77% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 7.0% (down 3881.0% YoY) and the FY2025 annual result came in at 7.0%, down 3881.0% from the prior year.
- Net Margin declined to 95.77% in Q4 2025, from 27.14% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 42.42% in Q4 2024 to a low of 114.26% in Q1 2021.
- A 5-year average of 18.48% and a median of 11.26% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2021 — Net Margin jumped 15346 bps — and 2025, when it plunged 13819 bps.
- Tracing ADMA's Net Margin over 5 years: stood at 24.52% in 2021, then climbed by 4 bps to 23.59% in 2022, then soared by 161 bps to 14.33% in 2023, then soared by 196 bps to 42.42% in 2024, then tumbled by 326 bps to 95.77% in 2025.
- The last three Net Margin figures came in at 95.77% (Q4 2025), 27.14% (Q3 2025), and 28.05% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 30.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.40% |
| Dec 31, 2025 | -95.77% |
| Sep 30, 2025 | 27.14% |
| Jun 30, 2025 | 28.05% |
| Mar 31, 2025 | 23.44% |
| Dec 31, 2024 | 42.42% |
| Sep 30, 2024 | 29.96% |
| Jun 30, 2024 | 29.91% |
| Mar 31, 2024 | 21.75% |
| Dec 31, 2023 | 14.33% |
| Sep 30, 2023 | 2.33% |
| Jun 30, 2023 | -10.60% |
| Mar 31, 2023 | -11.93% |
| Dec 31, 2022 | -23.59% |
| Sep 30, 2022 | -36.24% |
| Jun 30, 2022 | -18.33% |
| Mar 31, 2022 | -62.44% |
| Dec 31, 2021 | -24.52% |
| Sep 30, 2021 | -85.74% |
| Jun 30, 2021 | -105.56% |